...
首页> 外文期刊>Methods: A Companion to Methods in Enzymology >Antibody validation of immunohistochemistry for biomarker discovery: Recommendations of a consortium of academic and pharmaceutical based histopathology researchers
【24h】

Antibody validation of immunohistochemistry for biomarker discovery: Recommendations of a consortium of academic and pharmaceutical based histopathology researchers

机译:用于生物标志物发现的免疫组织化学的抗体验证:基于学术和药学的组织病理学研究人员财团的建议

获取原文
获取原文并翻译 | 示例

摘要

As biomarker discovery takes centre-stage, the role of immunohistochemistry within that process is increasing. At the same time, the number of antibodies being produced for "research use" continues to rise and it is important that antibodies to be used as biomarkers are validated for specificity and sensitivity before use. This guideline seeks to provide a stepwise approach for the validation of an antibody for immunohistochemical assays, reflecting the views of a consortium of academic and pharmaceutical based histopathology researchers. We propose that antibodies are placed into a tier system, level 1-3, based on evidence of their usage in immunohistochemistry, and that the degree of validation required is proportionate to their place on that tier. (C) 2014 The Authors. Published by Elsevier Inc.
机译:随着生物标记物发现成为中心阶段,免疫组织化学在该过程中的作用正在增加。同时,为“研究用途”而生产的抗体的数量继续增加,重要的是在使用前验证用作生物标记的抗体的特异性和敏感性。本指南旨在为免疫组织化学分析的抗体验证提供逐步方法,以反映学术和制药组织病理学研究人员联合会的观点。我们建议根据抗体在免疫组织化学中的使用证据,将抗体放入1-3级体系中,并且所需的验证程度与其在该层中的位置成正比。 (C)2014作者。由Elsevier Inc.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号